Spanish drug law 'will bring losses'

9 July 2006

The Spanish drug industry association Farmindustria has said that new legislation on drugs - the law on the "rational use of drugs and health care products" - will allow non-prescription drugs to be sold on the Internet. There will also be more aggressive reference prices as well as price cuts of up to 20% on drugs which have been on the market for more than 10 years and for which a generic equivalent is available at a lower price within the European Union.

Humberto Arnes, president of Farmindustria, said there was no economic justification for the measures and the proposed tax on drug company sales was "discriminatory." He added that the tax would lead to losses of some 125.0 million euros ($160.0 million) while total losses generated by the new law are estimated at 750.0 million euros.

The legislation in its final form has been approved by the Cortes, Spain's Parliament.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight